essening Organ dysfunction with VITamin C India (LOVIT India) trial

Phase 2

Completed

• Conditions: Health Condition 1: A419- Sepsis, unspecified organism

• Registration Number: CTRI/2020/03/024371
• Lead Sponsor: Apollo Hospitals Educational and Research Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-02-14
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

1.Patients >= 18 years old;

2.Admitted to the ICU with proven or suspected infection as the main diagnosis;

3.Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine).

Exclusion Criteria

1. > 24 hours of ICU admission;

2.Known Glucoseâ??6â??phosphate dehydrogenase (G6PD) deficiency;

3.Pregnancy;

4.Known allergy to vitamin C;

5.Known kidney stones within the past 1 year;

6.Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;

7.Expected death or withdrawal of lifeâ??sustaining treatments within 48 hours;

8.Previously enrolled in this study;

Study & Design

• Study Type: Interventional
• Study Design: Not specified